Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This refers to the combined or sequential administration of the **BCG (Bacillus Calmette-Guérin)** vaccine and the **measles vaccine** as evaluated in the **MATVAC (Maternal and Infant BCG and Measles Vaccination Study)**. Conducted by the **Bandim Health Project** in Guinea-Bissau, this phase 4 factorial randomized controlled trial investigates the **non-specific effects (NSE)** of these live attenuated vaccines. While BCG is traditionally used for tuberculosis and the measles vaccine for measles, research suggests these vaccines can strengthen the immune system against a broad range of unrelated infectious diseases through a process known as **trained immunity**. The MATVAC study specifically explores whether vaccinating mothers with these live vaccines can enhance the health, immunity, and survival of both the mothers and their infants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BCG vaccine + measles vaccine.